Posters - Posters
|
A Single Once Daily ABC/DTG/3TC Tablet Predicts Safe and Effective Exposures in Children 3 to <6kg
Chandasana H, Brooks KM, Buchanan AM, Tan L, Mujuru HA, Colbers A, Hopking J, Ciuffa M, McKenna M, Wiznia A, Brummel S, Bekker A, Cressey TR, Rabie H. Abstract: 944 at the Conference on Retroviruses and Opportunistic Infections (CROI); 2024 March 3-6; Denver, Colorado, USA. |
|
DOSE CONFIRMATION OF FOSFOMYCIN AND FLOMOXEF FOR EMPIRIC TREATMENT OF NEONATALSEPSIS
Adrie Bekker, NeoSEP1 Part1 Study team. E-Poster Discussion at 42nd annual meeting of the European Society for Paediatric Infectious Diseases (ESPID 2024); 2024 May 20-24; Copenhagen, Denmark & Online. |
|
Economic evaluation of a facility-based HIV and STIs self-screening program in northern Thailand
Phanthunane P, Konglumpun N, Salvadori N, Saebe N, Chompoopol A, Chairahaeng S, Piyarad S, Ponsuntikul T, Jourdain G. Poster presentation (TU PE E 573) at the 25th International AIDS Conference (AIDS 2024); 2024 July 22-26; Munich, Germany. |
|
Feasibility, acceptability and effectiveness of a nationwide, web application-guided, home-based HIV and syphilis selfscreening program in Thailand
Salvadori N, Piyarad S, Chairahaeng S, Ponsuntikul T, Kaewbundit A, Chalermpantmetagul S, Khamduang W, Ngo-Giang-Huong N, Pornprasert S, Ongwandee S, Jourdain G. Poster presentation (TH PE C 262) at the 25th International AIDS Conference (AIDS 2024); 2024 July 22-26; Munich, Germany. |
|
From awareness to use: PrEP cascade among at-risk individuals presenting for HIV screening in northern Thailand
Salvadori N, Akarasereenont T, Promnites P, Achalapong J, Nangola S, Kloypan C, Prompunt E, Wongplucksin N, Arunothong S, Sukrakanchana P, Chalermpantmetagul S, Khamduang W, Ngo-Giang-Huong N, Pornprasert S, Ongwandee S, Jourdain G. Poster presentation (WE PE C 195) at the 25th International AIDS Conference (AIDS 2024); 2024 July 22-26; Munich, Germany. |
|
High Drug Exposures in Neonates Using ABC/3TC Dispersible Tablets During the First Week of Life
Panjasawatwong N, Bekker A, Rabie H, Salvadori N, Toit S, Than-in-at K, Groenewald M, Capparelli E, Cressey R, Lallemant M, Cotton MF, Cressey TR. Abstract: 943 at the Conference on Retroviruses and Opportunistic Infections (CROI); 2024 March 3-6; Denver, Colorado, USA. |
|
Lamivudine (3TC) Dosing for Preterm Neonates Exposed to HIV
Bekker A, Capparelli E, Mirochnick M, Clarke DF, Cotton MF, Shapiro R, McCarthy K, Moye J, Violari A, Chokephaibulkit K, Abrams EJ, Penazzato M, Ruel T, Cressey TR. Abstract: 942 at the Conference on Retroviruses and Opportunistic Infections (CROI); 2024 March 3-6; Denver, Colorado, USA. |
|
Molnupiravir vs Favipiravir: An RCT in Outpatients At-Risk for COVID-19 in Thailand
Salvadori N, Jourdain G, Krittayaphong R, Siripongboonsitti T, Kongsaengdao S, Sakulkonkij P, Angkasekwinai N, Chusri S, Mekavuthikul T, Apisarnthanarak A, Srichatrapimuk S, Sangsawang S, Hanvoravongchai P, Sukrakanchana P, Auewarakul P. Abstract: 667 at the Conference on Retroviruses and Opportunistic Infections (CROI); 2024 March 3-6; Denver, Colorado, USA. |
|
No Significant Interactions From Hormone Therapy Toward F/TDF-Based PrEP in Trans Men: iMACT Study
Hiransuthikul A, Thammajaruk N, Kerr S, Janamnuaysook R, Nonenoy S, Hongchookiat P, Trichavaroj R, Tawon Y, Boonruang J, Teeratakulpisarn N, Cressey TR, Anderson PL, Phanuphak N. Abstract: 1145 at the Conference on Retroviruses and Opportunistic Infections (CROI); 2024 March 3-6; Denver, Colorado, USA. |
|
Population Pharmacokinetics of ABC/DTG/3TC FDC to Support Dosing in Peds With HIV-1: IMPAACT 2019
Chandasana H, Dijkman SC, Mehta R, Bush M, Rabie H, Flynn PM, Cressey TR, Acosta E, Brooks KM. Abstract: 945 at the Conference on Retroviruses and Opportunistic Infections (CROI); 2024 March 3-6; Denver, Colorado, USA. |
|
Potential Drug Interactions From Hormone Therapy Toward F/TAF-Based PrEP in Trans Men: iMACT Study
Hiransuthikul A, Thammajaruk N, Kerr S, Janamnuaysook R, Nonenoy S, Hongchookiat P, Trichavaroj R, Tawon Y, Boonruang J, Teeratakulpisarn N, Cressey TR, Anderson PL, Phanuphak N. Abstract: 1146 at the Conference on Retroviruses and Opportunistic Infections (CROI); 2024 March 3-6; Denver, Colorado, USA. |
|
Ravidasvir in combination with sofosbuvir for 12 or 24 weeks achieved high sustained virological response rates in genotype 3 chronic hepatitis C without or with compensated liver cirrhosis
Tan SS, Menétrey C, Ribeiro I, Salvadori N, Yerly S, Ngo-Giang-Huong N, Diap G. Poster presentation at EASL Congress; 2024 Jun 5-8; Milan, Italy. |
|
Simplifying Dosing by Harmonizing Weight-Band-Based Dosing Across Therapeutic Areas in Children
Waalewijn H, Almett M, Wasmann RE, Cressey TR, Easterbrook P, Olumese PE, Hesseling AC, Tarning J, Turkova A, Svensson E, Colbers A, Were WM, Denti P, Penazzato M. Abstract: 940 at the Conference on Retroviruses and Opportunistic Infections (CROI); 2024 March 3-6; Denver, Colorado, USA. |
|
Single-Dose PK/Safety of DTG-Dispersible Tablets in Neonates Supports Multi-Dosing: Petite-DTG Study
Bekker A, Salvadori N, Rabie H, Toit S, Than-in-at K, Groenewald M, Capparelli E, Owen A, Cressey R, Lallemant M, Cotton MF, Cressey TR. Abstract: 941 at the Conference on Retroviruses and Opportunistic Infections (CROI); 2024 March 3-6; Denver, Colorado, USA. |
|
User-Friendly and Efficient Multiplex HIV, Syphilis, and Hepatitis B and C Self-Screening in Thailand
Salvadori N, Achalapong J, Akarasereenont T, Nangola S, Kloypan C, Prompunt E, Wongpluesin N, Arunothong S, Khamduang W, Ngo-Giang-Huong N, Pornprasert S, Ongwandee S, Jourdain G. Abstract: 1101 at the Conference on Retroviruses and Opportunistic Infections (CROI); 2024 March 3-6; Denver, Colorado, USA. |
|
Validation of a Modified Pediatric Formulation of Sofosbuvir and Daclatasvir in Genotype-4 HCV-infected Children Weighing 17-35 Kg
Farrag A, Abbassi M, Ebeid F, Cressey T, Easterbrook P, Sabry N, El-Sayed M. Poster presentation at EASL Congress; 2024 Jun 5-8; Milan, Italy. |
|
INTERACTION BETWEEN TAF-BASED PrEP AND HORMONE THERAPY IN TRANSGENDER WOMEN: iFACT 3
Hiransuthikul A, Thammajaruk N, J.Kerr S, Janamnuaysook R, Nonenoy S, Hongchookiat P, Trichavaroj R, Tawon Y, Boonruang J, Teeratakulpisarn N, Cressey TR, Phanuphak N. Abstract: 996 at the Conference on Retroviruses and Opportunistic Infections (CROI); 2023 February 19-22; Seattle, Washington, USA. |
|
PK & SAFETY OF ABC/3TC DISPERSIBLE TABLETS & LPV/R GRANULES IN NEONATES: PETITE STUDY
Bekker A, Rabie H, Salvadori N, Du Toit S, Than-In-At K, Groenewald M, Capparelli E, Cressey R, Lallemant M, Cotton M, Cressey TR. Abstract: 826. at the Conference on Retroviruses and Opportunistic Infections (CROI); 2023 February 19-22; Seattle, Washington, USA. |
|
3-IN-1 RAPID BLOOD SELF-TESTING FOR HIV, HBV, AND HCV: ACCEPTABILITY AND FEASIBILITY
N. Salvadori, J. Achalapong, C. Boontan, S. Arunothong, W. Khamduang, P. Moolnoi, S. Pornprasert, S. Ongwandee, J Y. Mary, G. Jourdain, N. Ngo-Giang-Huong. Abstract: 814 at Conference on Retroviruses and Opportunistic Infections (CROI); 2022 February 12-16; Virtual. |
|
EFFICACY & SAFETY OF RAVIDASVIR + SOFOSBUVIR IN HEPATITIS C: STORM-C-1 FINAL RESULTS
S-S Tan, S. Thanprasertsuk, S. Thongsawat, N. Salvadori, C. Menétrey. Abstract: 528 at Conference on Retroviruses and Opportunistic Infections (CROI); 2022 February 12-16; Virtual. |
|
PHARMACOKINETICS OF ABACAVIR IN AFRICAN CHILDREN <14 KG DOSED PER WHO WEIGHT-BANDS
S. Chupradit, D.C Wamalwa, E. Maleche-Obimbo, A.R Kekitiinwa, J Mwanga-Amumpaire, E.A Bukusi, W.M Nyandiko, J.K Mbuthia, A. Swanson, T.R Cressey, B. Punyawudho, V. Musiime. Abstract: 735 at Conference on Retroviruses and Opportunistic Infections (CROI); 2022 February 12-16; Virtual. |
|
PHARMACOKINETICS/SAFETY OF DTG, ABC/3TC DISPERSIBLE TABLETS IN THAI CHILDREN
A. Premgamone, S. Anugulruengkitt, N. Wacharachaisurapol, C. Phasomsap, M. Tawan, T. Jupimai, C. Saisaengjan, Y. Tawon, TR. Cressey, T. Puthanakit. Abstract: 736 at Conference on Retroviruses and Opportunistic Infections (CROI); 2022 February 12-16; Virtual. |
|
Population Pharmacokinetics of Ravidasvir in HCV (+/- HIV) chronically infected adults with no or compensated cirrhosis in Thailand and Malaysia
Panjasawatwong N, Menétrey C, Ribeiro I, Salvadori N, Swanson A, Tan SS, Thanprasertsuk S, Thongsawat S, Cressey TR, and the STORM-C-1 study team. Poster: at International Workshop on Clinical Pharmacology of HIV, Hepatitis, and Other Antiviral Drugs 2022; 2022 Sep 19-20; Barcelona, Spain and online. |
|
A randomised comparison of DTG-based ART vs standard of care in infants and young children living with HIV weighing 3 to 14kg: results from the ODYSSEY trial
A. Lugemwa, H. Mujuru, B. Wynne, A. Violari, A. Kekitiinwa, C. Kityo, M. Archary, E. Variava, T. Sarfati, C. Shakeshaft, R. Turner, K. Nathoo, E. Chidziva, L. Atwine, N. Ramsagar, A. Liberty, P. Amuge, E. Kaudha, A. Nanduudu , R. Mngqibisa, R. Mosia, M. Cotton, T. Cressey, T. Puthanakit, A. Compagnucci, C. Giaquinto, P. Rojo, D. Ford, D.M Gibb, A. Turkova, ODYSSEY trial team. Abstract: PEBLB18 at 11th IAS Conference on HIV Science; 2021 July 18-21; Virtual event with a local partner hub in Berlin. |
|
Once-daily integrase inhibitor (INSTI) with boosted darunavir is non-inferior to standard of care in virologically suppressed children, Week 48 results of the SMILE PENTA-17 TRIAL
A. Compagnucci, M. Chan, Y. Saïdi, T. Cressey, A. Bamford, Y. Riault, A. Coelho, A. Nolan, S. Chalermpantmetagul, P. Amuge, V. Musiime, A. Violari, M. Cotton, S. Kanjanavanit, A. Volokha, R. Bologna, N. Pavia Ruz, L. Tato Prieto, P. Paioni, L. Marques, V. Reliquet, S. Welch, D. Ford, C. Giaquinto, D. Gibb, A. Babiker, J.T. Ramos Amador, and the SMILE-PENTA 17 Trial Group Abstract: PEB201 at 11th IAS Conference on HIV Science; 2021 July 18-21; Virtual event with a local partner hub in Berlin. |
|
Pharmacokinetics and safety of dispersible and immediate release FDC abacavir/dolutegravir/lamivudine in children with HIV weighing '¥14 kg: preliminary results from IMPAACT 2019
K. Brooks, J. Kiser, P. Samson, Y. Rani, S. Ward, T. Cressey, H. Cassim, J.G. Deville, G.R. Masheto, P.L. Ponatshego, A. Coletti, K. Lypen, I. Mustich, B. Heckman, M. Lojacono, R. Bowman, D. Yin, E. Townley, S. Majji, E.P. Acosta, K.J. Ryan, A.M. Buchanan, C.H. Brothers, H. Chandasana, H. Rabie, P. Flynn, on behalf of the IMPAACT 2019 Study Team. Abstract: PEBLB15 at 11th IAS Conference on HIV Science; 2021 July 18-21; Virtual event with a local partner hub in Berlin. |
|
Pharmacokinetics, safety and acceptability of a single dose of abacavir/lamivudine/lopinavir/ritonavir (4-in-1) fixed-dose granule formulation in neonates: PETITE study
A. Bekker, H. Rabie, N. Salvadori, S. du Toit, K. Than-in-at, M. Groenewald, I. Andrieux-Meyer, M. Kumar, E. Capparelli, M. Lallemant, M.F. Cotton, T.R. Cressey. Abstract: PEBLB16 at 11th IAS Conference on HIV Science; 2021 July 18-21; Virtual event with a local partner hub in Berlin. |
|
Poor concordance between objective and reported measures of pre-exposure prophylaxis (PrEP) adherence and factors associated with over-reported adherence among adolescent girls and young women (AGYW) in Kenya
J.d.D. Tapsoba, J. Cover, Y. Wang, K. Mori1, S. Zangeneh, S. Pasalar, S. Zobrist, A. Heyden2, T.R Cressey, C. Obong‘o, D.O. Madiang, M. Brady, P. Drain, A. Duerr, Y.Q. Chen. Abstract: PED618 at 11th IAS Conference on HIV Science; 2021 July 18-21; Virtual event with a local partner hub in Berlin. |
|
Virological failures and genotypic resistance in children and adolescents randomised to dolutegravir-based ART vs. standard-of-care in the ODYSSEY trial
C. Kityo, E. White, A. Turkova, H.A Mujuru, I. Nankya, B. Wynne, S. Ali, A. Kekitiinwa, A. Lugemwa, E. Kaudha, A. Liberty, H. Cassim, M. Archary, M. Cotton, L. Barlow-Mosha, T.R Cressey, C. Ngampiyasakul, U. Srirompotong, O. Behuhuma, Y. Saidi, A. Bamford, R. Kobbe, P. Rojo, C. Giaquinto, D. Gibb, D. Ford. Abstract: PEBLB17 at 11th IAS Conference on HIV Science; 2021 July 18-21; Virtual event with a local partner hub in Berlin. |
|
Weight gain in children and adolescents on dolutegravir vs standard of care in the ODYSSEY trial
A. Turkova, C. Kityo, H.A Mujuru, E. Variava, A. Kekitiinwa, A. Lugemwa, L. Barlow-Mosha, C. Ngampiyaskul, P. Zuidewind, T. Puthanakit, R. Mngqbisa, N.O. Behuhuma, H. Kataike, G. Musoro, A. Nandudu, P. Amuge, S. Makumbi, S. Danaviah, S. Ali, B. Wynne, Y. Riault, S. Welch, T.R Cressey, A. Violari, A. Compagnucci, J. Hakim P. Rojo, C. Giaquinto, D.M Gibb, D. Ford, the ODYSSEY trial team. Abstract: PEB202 at 11th IAS Conference on HIV Science; 2021 July 18-21; Virtual event with a local partner hub in Berlin. |
